SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

MNKD RSS Feed
Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, TREND1, lakingsphan0427 , Phaeton, $Pistol Pete$
Search This Board: 
Last Post: 10/22/2017 12:58:25 PM - Followers: 398 - Board type: Free - Posts Today: 5


FDA LABEL
http://hcp.afrezza.com/afrezza.pdf    


     WEEKLY NUMBERS     http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116919069
Quote:
Many Afrezza users have reported rapid drops in A1c

Yeah, but in the only clinical trials that compared Afrezza to rapid acting insulins, Afrezza did no such thing.

Straight from the label:

Absolute HgA1c reduction:
Afrezza : 0.21
Rapid I : 0.40

% of patients reducing by 7% or more:
Affreza: 13.8%
Rapid I: 27.1%

And there is your problem. Tweets do not counter clinical trial data.

Afrezza avoids the needle, for sure.But is it better?

It has a faster/narrower spike. BUT, to take advantage of this, the user need to know how to use it.

Perhaps a few users have got it down, and do better. But that does not work for the masses.

MNKD really needs to figure out how to work with the new electronic glucose monitors to solve this issue.        

 p.s. Reading the Mannkind report at FDA.GOV provides plenty of clues why Afrezza is a failure.

https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390865.pdf        
 

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf



 
MANNKIND CORP

Alfred E. Mann, Founder (Deceased)

Alfred E. Mann had been one of MNKD's directors since April 1999, Chairman of the Board since December 2001 and  Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mannkindcorp.com/

http://www.mnkd.proboards.com/  A good forum for discussion on Mankind

http://finance.yahoo.com/q/ks?s=MNKD

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.



Nasdaq.com;
http://www.nasdaq.com/symbol/mnkd/institutional-holdings
Sec.gov;
http://www.sec.gov/cgi-bin/browse-edgar?CIK=Mnkd&Find=Search&owner=exclude&action=getcompany
 
MNKD CHART

 
 


 

 

SureTrader
Interactive Brokers Advertisement
MNKD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD News: Statement of Changes in Beneficial Ownership (4) 10/13/2017 05:04:55 PM
MNKD News: MannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico 10/12/2017 09:00:00 AM
MNKD News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 10/11/2017 05:20:09 PM
MNKD News: Current Report Filing (8-k) 10/11/2017 05:10:48 PM
MNKD News: Current Report Filing (8-k) 10/11/2017 08:01:51 AM
PostSubject
#25986  Sticky Note MNKD DAY and 30 MIN TREND1 10/10/17 12:28:22 PM
#23743  Sticky Note $MNKD MannKind and Biomm Enter Into Distribution Agreement $Pistol Pete$ 06/01/17 01:49:35 AM
#23541  Sticky Note Buffalo teacher a key advocate in breakthrough diabetes drug Phaeton 05/19/17 12:07:29 PM
#26418   You are asking for a long term entry TREND1 10/22/17 12:58:25 PM
#26417   Ok tool dmcc2087 10/22/17 11:18:43 AM
#26416   https://pbs.twimg.com/media/DMOPuZoV4AAD-q9.jpg WHS 10/22/17 07:39:47 AM
#26415   Over sold is not an actionable event. TREND1 10/22/17 04:07:30 AM
#26414   Oversold here dmcc2087 10/22/17 12:47:13 AM
#26413   This article gives some good backfill to the XenaLives 10/21/17 04:50:29 PM
#26411   Good thoughts MNKD load the boat lol dmcc2087 10/21/17 09:06:52 AM
#26410   2 years ago over $10 once it was dmcc2087 10/21/17 09:05:59 AM
#26409   LOOKING FOR RENRY POINT, THOUGHTS ??? biotech2 10/21/17 05:47:37 AM
#26408   Schwab giving back borrowed shares to owners. Interest Hypi 10/20/17 10:21:16 PM
#26407   Here is hoping MNKD goes down to 2 TREND1 10/20/17 10:02:52 PM
#26406   What is this $50 you are talking about ? TREND1 10/20/17 09:48:24 PM
#26405   I hope you are right. TREND1 10/20/17 09:47:13 PM
#26404   Very funny, billionaire knows more than you! youtoo 10/20/17 09:35:12 PM
#26403   Once $50 trend is going BACK UP imo dmcc2087 10/20/17 09:27:15 PM
#26402   billionaire is wrong. TREND1 10/20/17 09:22:33 PM
#26401   2017 is much better than last year! youtoo 10/20/17 09:13:13 PM
#26398   RSI reset & volume picking up dmcc2087 10/20/17 08:41:38 PM
#26397   Volume, patents, FDA approval dmcc2087 10/20/17 08:40:28 PM
#26396   One must do their DD TREND1 10/20/17 08:29:32 PM
#26395   It may be going back to 7 or TREND1 10/20/17 07:54:33 PM
#26394   I think it does. The trend is always TREND1 10/20/17 07:47:08 PM
#26393   Going back to $7.00 don't listen to the dmcc2087 10/20/17 07:29:29 PM
#26392   Doesn't mean anything dmcc2087 10/20/17 07:29:10 PM
#26390   Aftermarket not holding up either DJ Kazi 10/20/17 06:48:01 PM
#26387   SORRY. But the last 30 min confirmed the TREND1 10/20/17 04:30:26 PM
#26386   Great day excited for next week! MNKD dmcc2087 10/20/17 04:20:11 PM
#26385   Trend down TREND1 10/20/17 02:02:51 PM
#26384   Looking great today. We see New highs ($7+) OTC BB King 10/20/17 01:10:45 PM
#26383   And yes... I bought more yesterday at $3.97 martind18 10/20/17 01:01:54 PM
#26382   If you think MNKD is finished... and the martind18 10/20/17 01:00:53 PM
#26381   Xena, I do agree the heavy short interest exwannabe 10/20/17 12:58:52 PM
#26380   Possible - but I haven't traded anything with XenaLives 10/20/17 11:31:22 AM
#26379   $5.25 Monday? It's just a feeling dmcc2087 10/20/17 11:27:08 AM
#26378   Should of put in more yesterday at $3.80 DJ Kazi 10/20/17 11:23:52 AM
#26375   Options are really active - XenaLives 10/20/17 11:00:09 AM
#26374   Meanwhile MNKD is up 10% dmcc2087 10/20/17 10:59:06 AM
#26371   Next wave up dmcc2087 10/20/17 10:52:49 AM
#26369   There is a reason MNKD was able to XenaLives 10/20/17 10:50:45 AM
#26363   Looking good to me! Stockstrodamus 10/20/17 09:53:14 AM
#26362   Starts out green to trick people than will DJ Kazi 10/20/17 09:33:09 AM
#26360   Have some patience, you can't expect to jump DJ Kazi 10/20/17 09:13:30 AM
#26356   Scripts numbers for 10/13/17 exwannabe 10/20/17 08:59:52 AM
#26353   Will be Green today.. ;) leonardo1 10/20/17 08:51:44 AM
#26351   I was looking promising this morning but now DJ Kazi 10/20/17 08:50:30 AM
#26346   Pre-market volume is pretty low, people are scared DJ Kazi 10/20/17 08:14:17 AM
#26345   Is today the big coverday day for the leonardo1 10/20/17 08:05:10 AM
#26344   Diabetes is inherited TREND1 10/20/17 06:35:05 AM
#26343   Not always true about eating right. My brother DJ Kazi 10/20/17 06:20:39 AM
#26340   Hope so - pure manipulation No news - joro44 10/19/17 11:22:43 PM
PostSubject